PET imaging of noradrenaline transporters in Parkinson's disease: focus on scan time.
Locus coeruleus
Noradrenaline transporter
Parkinson’s disease
Positron emission tomography
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
01
10
2018
accepted:
01
10
2018
pubmed:
8
10
2018
medline:
21
5
2019
entrez:
8
10
2018
Statut:
ppublish
Résumé
In subjects with idiopathic Parkinson's disease (PD) the functional state of the locus coeruleus and the subtle derangements in the finely tuned dopamine-noradrenaline interplay are largely unknown. The PET ligand (S,S)-[ Ten patients with idiopathic PD underwent dynamic C-11 MRB PET (120 min duration) and brain magnetic resonance imaging. Model-based (i.e., simplified and multilinear reference tissue model 2) non-displaceable binding potentials (BP) of selected brain regions were analyzed for a 90 min scan protocol and compared with BP derived from static 30-min data with different starting times (30, 40, 50 and 60 min) after C-11 MRB injection. Intraclass correlation coefficient and linear regression analysis were used to explore the association between BP of different scan durations. Spearman's ρ served to describe the correlation of BP with demographic and clinical parameters. With respect to kinetic models, BP An acquisition time of 30 min, starting 50 or 60 min after C-11 MRB injection, allows a reliable estimation of noradrenaline transporter binding values in Parkinsonian people. A short acquisition time can significantly reduce the discomfort of Parkinsonian patients and facilitate PET studies, especially in the medication-off-state.
Identifiants
pubmed: 30293197
doi: 10.1007/s12149-018-1305-5
pii: 10.1007/s12149-018-1305-5
pmc: PMC6373329
doi:
Substances chimiques
Norepinephrine Plasma Membrane Transport Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-77Références
Mov Disord. 2000 Jul;15(4):692-8
pubmed: 10928580
Mov Disord. 2002 Jul;17(4):782-8
pubmed: 12210876
J Cereb Blood Flow Metab. 2002 Dec;22(12):1440-52
pubmed: 12468889
Hum Brain Mapp. 2003 Aug;19(4):224-47
pubmed: 12874777
J Cereb Blood Flow Metab. 2003 Sep;23(9):1096-112
pubmed: 12973026
Nature. 1957 Nov 30;180(4596):1200
pubmed: 13483658
Synapse. 2003 Dec 15;50(4):345-52
pubmed: 14556239
Chirality. 2004 Aug;16(7):475-81
pubmed: 15236345
Brain. 2005 Jun;128(Pt 6):1314-22
pubmed: 15716302
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
J Neurochem. 2005 Jul;94(2):337-51
pubmed: 15998285
Brain Res. 1990 Jul 16;523(1):134-8
pubmed: 1698514
Biochem Pharmacol. 2007 Jul 15;74(2):177-90
pubmed: 17416354
Nucl Med Biol. 2007 Aug;34(6):667-79
pubmed: 17707807
Neuroreport. 2007 Sep 17;18(14):1499-502
pubmed: 17712282
Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):424-38
pubmed: 17968545
Exp Neurol. 2008 Jul;212(1):226-9
pubmed: 18501351
Brain. 1991 Oct;114 ( Pt 5):2283-301
pubmed: 1933245
Neuroimage. 2009 Oct 1;47(4):1261-7
pubmed: 19524044
Synapse. 2010 Jan;64(1):30-8
pubmed: 19728366
Biol Psychiatry. 2010 Nov 1;68(9):854-60
pubmed: 20691429
Neuroimage. 2011 May 1;56(1):268-79
pubmed: 20869448
Ann Neurol. 2011 May;69(5):803-10
pubmed: 21246604
BMC Neurol. 2011 Jul 21;11:88
pubmed: 21777421
Front Hum Neurosci. 2012 Jan 03;5:179
pubmed: 22287946
JAMA Psychiatry. 2013 Nov;70(11):1199-205
pubmed: 24048210
Mov Disord. 2014 Dec;29(14):1710-9
pubmed: 25297066
Front Neurol. 2014 Dec 15;5:242
pubmed: 25566170
Nucl Med Biol. 2016 May;43(5):318-23
pubmed: 27150035
J Nucl Med. 2017 Jul;58(7):1140-1145
pubmed: 27980046
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1056-1064
pubmed: 28066877
J Nucl Med. 2018 Apr;59(4):659-664
pubmed: 28848039
Ann Clin Transl Neurol. 2017 Aug 11;4(9):632-639
pubmed: 28904985
Brain. 2018 Feb 1;141(2):496-504
pubmed: 29272343
N Engl J Med. 1968 Mar 14;278(11):630
pubmed: 5637779
IEEE Trans Med Imaging. 1998 Jun;17(3):463-8
pubmed: 9735909